Amount of eligible clients: CDEC discussed the uncertainty in the number of patients with moderately critical to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some clients that are labeled as acquiring moderate or reasonable condition could have a extreme bleeding phenotype, https://juliusedayg.tribunablog.com/hemgenix-for-dummies-50413263